Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss
Home>Topics>>Arca Biopharma Rallies On New Plans For A Phase III Trial

Arca Biopharma Rallies On New Plans For A Phase III Trial

Long Investing Ideas from Seeking Alpha

Mon, 4 Feb 2013

By Brian L. Wilson : Arca Biopharma (NASDAQ: ABIO ) was a very boring ticker in 2013 until the company provided an update on a proposed clinical trial for atrial fibrillation for the company's flagship drug Gencaro (bucindolol hydrochloride) after the closing bell on January 29th. The market's ...

Read the rest of this article on Long Investing Ideas from Seeking Alpha

Related Topics:

  1. NASDAQ
Content Partners
Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
International Sites: Australia Canada China France Germany Hong Kong Italy The Netherlands Norway Spain U.K. Switzerland India Finland
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.